Angion Biomedica Corp

ANGN

NASDAQ. Currency in USD

0.82 -0.03 ( -3.29% )

Real time prices: December 01

Market Cap.
24.69M
Beta (5Y monthly)
-
Price/Earnings
-
EPS (TTM)
-0.50
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
31,637
1y Target Est.
1.50
Day's Range
0.81
-
0.85
52 Week's Range
0.78
-
3.71

Historical Summary

Performance
EPS growth
Share Buybacks

About Angion Biomedica Corp

Sector
Healthcare
Industry
Biotechnology
Website
https://www.angion.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
29.96M
Employees
71
Address
51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Latest news

Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the...
By Zacks Investment Research - 2 days ago

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous...
By Zacks Investment Research - 2 days ago

Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy...
By Zacks Investment Research - 2 days ago

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase...
By Zacks Investment Research - 3 days ago

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy...
By Zacks Investment Research - 6 days ago

BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory...
By Zacks Investment Research - 1 week ago

Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating...
By Zacks Investment Research - 1 week ago

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved...
By Zacks Investment Research - 1 week ago